China NMPA Inspection - Gansu Big Handprint Rose Technology Co., Ltd. - October 20, 2025

The National Medical Products Administration (NMPA) conducted an unannounced inspection of Gansu Dashouyin Rose Technology Co., Ltd., with the findings announced on October 20, 2025 (NMPA Announcement No. 36 of 2025). This regulatory action revealed critical violations of the "Cosmetics Supervision and Administration Regulations" and the "Cosmetics Production Quality Management Standards." Investigators specifically identified serious deficiencies within the company's production quality management system, indicating a failure to adhere to established safety and quality protocols for cosmetic manufacturing. These shortcomings were deemed significant enough to potentially compromise public safety concerning cosmetic products. In response, the NMPA has directed the Gansu Provincial Drug Administration to thoroughly investigate the suspected illegal activities and enforce legal penalties. Consequently, Gansu Dashouyin Rose Technology Co., Ltd. has been ordered to immediately cease all production and operational activities. The company is also required to promptly address and rectify the identified systemic problems to restore compliance with national standards. This decisive action by the NMPA emphasizes the regulatory body's commitment to ensuring product integrity and consumer protection within the cosmetics sector.